Capricor Therapeutics (CAPR) News Today $17.77 +0.63 (+3.68%) (As of 10/11/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period $1000 Invested In This Stock 5 Years Ago Would Be Worth $6,800 TodayOctober 12 at 6:26 AM | benzinga.comCapricor Announces Long-Term Data From HOPE-2 OLE Study Of Deramiocel For DMD Treatment; Stock UpOctober 12 at 6:26 AM | markets.businessinsider.comCapricor Therapeutics Says Duchenne Muscular Dystrophy Candidate Shows Sustained Cardiac, Skeletal Benefits After 3 YearsOctober 12 at 6:26 AM | finance.yahoo.comCapricor Therapeutics Inc (NASDAQ:CAPR) Receives Consensus Recommendation of "Buy" from AnalystsShares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) have earned a consensus recommendation of "Buy" from the five research firms that are covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a buy rating. The average 12 month price objective amoOctober 12 at 3:36 AM | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Shares Gap Up - What's Next?Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up - Still a Buy?October 11 at 12:25 PM | marketbeat.comCapricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society CongressOctober 11 at 9:15 AM | globenewswire.com89,314 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Acquired by Marshall Wace LLPMarshall Wace LLP bought a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 89,314 shares of the biotechnology company's stock, valued at approxOctober 11 at 3:16 AM | marketbeat.comCapricor Therapeutics Inc (CAPR) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...October 10 at 4:37 PM | finance.yahoo.comBuy Rating Affirmed for Capricor Therapeutics Amid Promising Developments in DMD-cardiomyopathy TreatmentOctober 10 at 4:37 PM | markets.businessinsider.comCapricor Therapeutics Initiates FDA Rolling Submission for Duchenne Muscular Dystrophy Treatment October 10 at 6:53 AM | americanbankingnews.comCapricor Therapeutics (NASDAQ:CAPR) Rating Reiterated by HC WainwrightOctober 9 at 2:50 PM | americanbankingnews.comCapricor Therapeutics (NASDAQ:CAPR) Stock Price Down 7% - Should You Sell?October 9 at 1:09 PM | americanbankingnews.comCapricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular DystrophyOctober 9 at 9:15 AM | globenewswire.comRenaissance Technologies LLC Acquires 84,350 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)Renaissance Technologies LLC boosted its holdings in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 158.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 137,500 shares of the biotechnoloOctober 9 at 3:15 AM | marketbeat.comOppenheimer Keeps Their Buy Rating on Capricor Therapeutics (CAPR)October 8, 2024 | markets.businessinsider.comCapricor Therapeutics (NASDAQ:CAPR) Sees Unusually-High Trading Volume - Should You Buy?October 7, 2024 | americanbankingnews.comCapricor Therapeutics (NASDAQ:CAPR) Sees Strong Trading Volume - Here's What HappenedCapricor Therapeutics (NASDAQ:CAPR) Sees Unusually-High Trading Volume - Still a Buy?October 7, 2024 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Shares Gap Up - Still a Buy?October 6, 2024 | americanbankingnews.comCapricor Therapeutics (NASDAQ:CAPR) Trading 4.1% Higher - Here's What HappenedOctober 5, 2024 | americanbankingnews.comMarketBeat Week in Review – 9/30 - 10/4 (CAPR)A strong jobs report and a temporary settlement of the port strike lifted stocks but inflation and earnings data could set investors up for more volatilityOctober 5, 2024 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Shares Gap Down - Here's What HappenedOctober 4, 2024 | americanbankingnews.comCapricor Therapeutics (NASDAQ:CAPR) Shares Gap Up - Should You Buy?Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up - Here's WhyOctober 4, 2024 | marketbeat.comCapricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society CongressOctober 4, 2024 | globenewswire.comCapricor Therapeutics (NASDAQ:CAPR) Trading Up 4.1%Capricor Therapeutics (NASDAQ:CAPR) Trading 4.1% HigherOctober 3, 2024 | marketbeat.comIs Capricor Therapeutics, Inc. (CAPR) the Best Russell 2000 Stock to Buy According to Analysts?October 3, 2024 | msn.comCapricor Therapeutics (NASDAQ:CAPR) Sets New 12-Month High at $17.61October 3, 2024 | americanbankingnews.comCapricor Therapeutics (NASDAQ:CAPR) Shares Gap Down to $15.01Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Down to $15.01October 2, 2024 | marketbeat.comCapricor Therapeutics Target of Unusually High Options Trading (NASDAQ:CAPR)October 2, 2024 | americanbankingnews.comCapricor Therapeutics (NASDAQ:CAPR) Hits New 1-Year High at $17.61Capricor Therapeutics (NASDAQ:CAPR) Hits New 1-Year High at $17.61October 1, 2024 | marketbeat.comStock Traders Purchase High Volume of Capricor Therapeutics Call Options (NASDAQ:CAPR)Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders acquired 13,044 call options on the stock. This represents an increase of approximately 748% compared to the average volume of 1,538 call options.October 1, 2024 | marketbeat.comHere's How Much $100 Invested In Capricor Therapeutics 5 Years Ago Would Be Worth TodaySeptember 30, 2024 | benzinga.comCapricor Therapeutics Is Up Over 100%, Could Rise Even HigherCapricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathySeptember 30, 2024 | marketbeat.comCheck Out Last Week's Big Insider Buying: Biotechs, Energy, and MoreSeptember 29, 2024 | 247wallst.comFY2024 EPS Estimates for Capricor Therapeutics Inc (NASDAQ:CAPR) Lifted by AnalystCapricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Equities research analysts at Cantor Fitzgerald raised their FY2024 EPS estimates for Capricor Therapeutics in a research note issued on Wednesday, September 25th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology coSeptember 27, 2024 | marketbeat.comCapricor: DMD Treatment Focus With Deramiocel Is Likely To Pay OffSeptember 26, 2024 | seekingalpha.comMaxim Group Increases Capricor Therapeutics (NASDAQ:CAPR) Price Target to $25.00Maxim Group raised their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research note on Wednesday.September 25, 2024 | marketbeat.comShinyaku Co Ltd Nippon Acquires 2,798,507 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) StockSeptember 25, 2024 | insidertrades.comCapricor Therapeutics Shares Rise in Premarket on Plans to File Application for DeramiocelSeptember 24, 2024 | marketwatch.comBuy Rating Affirmed for Capricor Therapeutics on Promising DMD-cardiomyopathy Treatment ProspectsSeptember 24, 2024 | markets.businessinsider.comCapricor surges on plans to seek FDA approval for lead assetSeptember 24, 2024 | seekingalpha.comWave Life And Capricor Surge Forward With Hope - Are These Stocks In Your Portfolio?September 24, 2024 | markets.businessinsider.comWhy Capricor Therapeutics Stock Is Soaring TuesdaySeptember 24, 2024 | benzinga.comHC Wainwright Reaffirms "Buy" Rating for Capricor Therapeutics (NASDAQ:CAPR)HC Wainwright restated a "buy" rating and set a $40.00 price target on shares of Capricor Therapeutics in a report on Tuesday.September 24, 2024 | marketbeat.comCapricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024September 23, 2024 | globenewswire.comWeek In Review: Nippon Shinyaku Signs $735m Deal For DMD TherapySeptember 22, 2024 | seekingalpha.comCapricor Therapeutics Poised for Growth with Expanded Deramiocel Partnership and Positive Phase 3 OutlookSeptember 18, 2024 | markets.businessinsider.comCapricor Therapeutics (NASDAQ:CAPR) Stock Quotes, Forecast and News SummarySeptember 18, 2024 | benzinga.comCapricor Therapeutics partners with Nippon Shinyaku for European commercialization of DeramiocelSeptember 18, 2024 | msn.comBuy Rating Affirmed for Capricor Therapeutics Amidst Expanded Partnership and Regulatory AdvancementsSeptember 18, 2024 | markets.businessinsider.comCapricor Collaborates With Nippon Shinyaku For European Expansion Of Deramiocel For DMD; Stock UpSeptember 18, 2024 | markets.businessinsider.com Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Must-backed energy grid could save us all (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, CAPR Media Mentions By Week CAPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CAPR News Sentiment▼0.660.77▲Average Medical News Sentiment CAPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CAPR Articles This Week▼223▲CAPR Articles Average Week Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CLSD News Today LPTX News Today PRPH News Today EYEN News Today GLMD News Today TNXP News Today NRBO News Today ACAD News Today IDYA News Today CPRX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CAPR) was last updated on 10/12/2024 by MarketBeat.com Staff From Our PartnersAI Expert Reveals New PickYour Financial Planner Won't Tell You About This Investment Strategy Silicon Valley insider Jeff Brown has ...Brownstone Research | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe Great Crypto Frenzy 2.0 is About to StartBitcoin’s Final Bull Run: Three Altcoins to Get Into NOW! “Crypto Whisperer” Ian King is calling it: due to...Banyan Hill Publishing | SponsoredNotice: Major payout due November 19th - are you on the list?On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's p...Behind the Markets | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
